Targeted biomedicines to debut at CIIE and bring relief to patients

Sanofi participates in the CIIE for the 5th consecutive year.

The China International Import Expo is in its fifth year. Over the past five years, the CIIE has become an important platform for the world to share China’s development opportunities. As a global leader in pharmaceutical and healthcare innovation, Sanofi has participated in the CIIE for five consecutive years. Again this year, the company will be showcasing a new drug for children 6 months to 5 years old called Dupixent® (Dupilumab). The product treats inflammation-induced atopic dermatitis (AD) type 2, aiming to meet the health needs of younger patients with AD and to accelerate an innovative treatment plan to benefit patients of all ages who are affected by AD.

In recent years, Sanofi has continued to advance scientific development as well as standards and models for AD diagnosis and treatment and promoted the improvement of standardized diagnosis and treatment systems and long-term management of AD. in China. It is reported that the special issue of “100 questions and answers for Chinese patients with Alzheimer’s disease” jointly published by more than 20 authoritative experts in the field of dermatology, supported by Sanofi, sponsored by the professional committee Dermatology Rehabilitation Program of the Chinese Rehabilitation Medical Association, and led by Professor Zhang Jianzhong, Director of the Department of Dermatology of Peking University People’s Hospital, will also be unveiled at this year’s CIIE.

Cablivi®, the world’s first approved nanobody drug and targeted drug for the treatment of Acquired Thrombocytopenic Thrombotic Purpura (TTTP), was nominated for this year’s “Best Biotechnology Product Award” at the Galen Awards and will also be featured at the CIIE. A next-generation enzyme replacement therapy (ERT) drug for the treatment of Pompe disease, Nexviazyme®, will also be introduced to the public for the first time at the 5th CIIE. Nexviazyme® has already received “Breakthrough Therapy” designation from the FDA. The drug can significantly improve respiratory function and exercise capacity in patients with Pompe disease and aims to become the standard treatment for Pompe disease.

Comments are closed.